45 drugs enter the first batch of low price purchase catalogue

On December 9, the joint procurement office of Wuhan pharmaceutical machinery issued the detailed rules for the implementation of the first batch of centralized drug volume procurement in Wuhan in 2019 and the first batch of centralized drug volume procurement catalogue in Wuhan in 2019, with 45 drugs released into the first batch of procurement catalogue According to the published implementation rules, this catalogue is determined in the drugs purchased by the state and Hubei Province, and the range of the selected varieties is the drugs and class II psychotropic drugs that are online in the "Hubei provincial centralized purchasing service platform for medical devices" and have trading volume in medical institutions in Wuhan area before June 30, 2019 Wuhan requires that the quoted price of enterprises shall not be higher than the lowest price of the national provincial network on December 1, 2019 (referred to as the national lowest price, excluding Fujian, Guangdong and Chongqing) On the basis of the lowest price in the country, the highest price limit of quotation shall be formulated according to the quality level, the volume price relationship of the actual amount used in the previous year and the operation of Wuhan Medical Insurance Fund The proportion of actual consumption of different quality levels of the same generic name in 2018 is more than 50%, which is listed as group A, and the proportion less than 50% is listed as group B A The price limit principle of group B is 0.8 and 0.9 times of the lowest price in China respectively However, Wuhan's rules of volume purchase are more prominent in the link between volume and price Group A enterprises shall offer 50%, 70% and 80% of the purchase volume gradient of the bargaining base of varieties, and the decline of each gradient shall not be less than 5% of the competitive offer In group B, 20%, 40% and 50% of the purchase volume are quoted in gradient, and the decline of each gradient shall not be less than 5% of the competitive quotation If an enterprise wants to purchase more than 50% of the dog's purchase volume, its quotation reduction shall be at least 50% of that of the selected enterprises in group A Wuhan, an innovative gradient quotation, closely links volume and price It is possible to reduce price before purchasing volume It will make enterprises bid more cautiously, perhaps by a larger margin This kind of model can promote enterprise bidding, make the volume price linkage more direct, to the affirmation of the National Health Insurance Bureau On November 21, when the director of the state medical security bureau investigated the drug use guarantee and centralized drug volume purchase in the outpatient department of hypertension and diabetes in Wuhan, Hubei Province, he fully affirmed the exploration of centralized drug volume purchase in Wuhan It is emphasized that on the basis of conscientiously implementing the results of the expansion of centralized drug volume procurement organized by the state, all regions are encouraged to explore and establish a normalized centralized drug volume procurement system, and to study the expansion of the procurement scope to high-value medical consumables and non over evaluated drugs At the same time, Wuhan municipal government issued the work plan for centralized drug volume procurement on November 28, which indicates that one of the objectives of implementing the volume procurement is to provide replicable promotion experience for the implementation of centralized drug volume procurement in the national medical insurance overall planning area Perhaps Wuhan mode will be the reference for more provinces and cities to purchase with volume in the next step, but it is certain that the purchase linked with volume and price will be extended in a deeper and broader scope.